Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ZQB
|
|||
| Drug Name |
KPT-9274
|
|||
| Synonyms |
Pak4-IN-1; PAK4-IN-1; 1643913-93-2; UNII-9T56TV18X7; 9T56TV18X7; SCHEMBL16345416; SCHEMBL16348032; KPT9274; EX-A563; BCP10637; KPT 9274;KPT9274; ZINC253387914; AKOS030526635; CS-5146; SB19836; PAK4-IN-1 pound KPT9274 pound(c); NCGC00484085-01; HY-12793; J-690230; 2-Propenamide, 3-(6-amino-3-pyridinyl)-N-((5-(4-((4,4-difluoro-1-piperidinyl)carbonyl)phenyl)-7-(4-fluorophenyl)-2-benzofuranyl)methyl)-, (2E)-; 4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide; (E)-3-(6-aminopyridin-3-
Click to Show/Hide
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | ||
| Company |
Karyopharm Therapeutics Newton, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C35H29F3N4O3
|
|||
| Canonical SMILES |
C1CN(CCC1(F)F)C(=O)C2=CC=C(C=C2)C3=CC(=C4C(=C3)C=C(O4)CNC(=O)C=CC5=CN=C(C=C5)N)C6=CC=C(C=C6)F
|
|||
| InChI |
1S/C35H29F3N4O3/c36-28-9-7-24(8-10-28)30-19-26(23-3-5-25(6-4-23)34(44)42-15-13-35(37,38)14-16-42)17-27-18-29(45-33(27)30)21-41-32(43)12-2-22-1-11-31(39)40-20-22/h1-12,17-20H,13-16,21H2,(H2,39,40)(H,41,43)/b12-2+
|
|||
| InChIKey |
MRFOPLWJZULAQD-SWGQDTFXSA-N
|
|||
| CAS Number |
CAS 1643913-93-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | PAK-4 protein kinase (PAK4) | Target Info | Inhibitor | [1] |
| KEGG Pathway | ErbB signaling pathway | |||
| Ras signaling pathway | ||||
| Axon guidance | ||||
| Focal adhesion | ||||
| T cell receptor signaling pathway | ||||
| Regulation of actin cytoskeleton | ||||
| MicroRNAs in cancer | ||||
| Renal cell carcinoma | ||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Inflammation mediated by chemokine and cytokine signaling pathway | ||||
| Pathway Interaction Database | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| CDC42 signaling events | ||||
| FGF signaling pathway | ||||
| WikiPathways | ErbB Signaling Pathway | |||
| Regulation of Actin Cytoskeleton | ||||
| Focal Adhesion | ||||
| Integrin-mediated Cell Adhesion | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.